Bromantane vs RAD-140
Moderate Research vs Emerging
avoid Mechanism-based · 53% Both Bromantane and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Bromantane RAD-140
Weight 277.18 Da 393.83 Da
Half-life ~11 hours ~60 hours
Type Adamantane-bromophenyl derivative (C16H20BrN) Nonsteroidal selective androgen receptor modulator (C20H16ClN5O2)
Key Benefits
Bromantane
01 Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
02 Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
03 Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
04 Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
05 Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
06 Smooth onset and offset with no crash or rebound effects
RAD-140
01 Potent anabolic activity in muscle tissue with high oral bioavailability
02 Tissue-selective action sparing the prostate and other androgen-sensitive organs
03 No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
04 No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
05 Long half-life (~60 hours) permitting convenient once-daily oral dosing
06 Neuroprotective properties observed in preclinical models
07 Increased lean body mass and reduced fat mass in preclinical studies
Side Effects
Bromantane
Insomnia or difficulty falling asleep (if taken too late in the day)
Mild anxiety or restlessness at higher doses (above 100 mg)
Mild headache (uncommon, typically transient)
RAD-140
Testosterone suppression (dose-dependent, occurs in virtually all users by week 4-6)
Liver enzyme elevation (ALT, AST increases reported in clinical and anecdotal data)
Hair shedding (temporary, typically resolves after discontinuation)
Headaches (most common in the first 1-2 weeks, often transient)
Nausea (mild, usually with initial doses or on an empty stomach)
Lipid disruption (HDL suppression, LDL elevation)
Mild insomnia or sleep disturbance
Reduced libido and mood changes related to testosterone suppression
Contraindications
Known hypersensitivity to bromantane or adamantane derivatives
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic impairment
Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer, certain breast cancers not being treated under clinical supervision)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient safety data for this population)
Research Evidence
Bromantane RAD-140
Status Moderate Research Emerging
References 5 studies 5 studies
Latest — July 2020
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.